Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Axelsson

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Chemosphere|August 8, 2024
Sampling of per- and polyfluoroalkyl substances in drainage water from a waste management facilityMio Pettersson, Ingrid Ericson Jogsten, Patrick van Hees, et al.
Frontiers in Neurology|April 3, 2023
The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective surveySofia Sandgren, Lenka Novakova, Markus Axelsson, et al.
Plos One|April 4, 2018
Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkersLenka Novakova, Markus Axelsson, Clas Malmeström, et al.
European Journal of Neurology|April 17, 2026
Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple SclerosisIgal Rosenstein, Markus Axelsson, Magnus Johnsson, et al.
Multiple Sclerosis and Related Disorders|October 11, 2021
Follow-up after infectious mononucleosis in search of serological similarities with presymptomatic multiple sclerosisDaniel Jons, Linn Persson Berg, Peter Sundström, et al.
European Journal of Neurology|June 14, 2023
Presence of neural surface and onconeural autoantibodies in cerebrospinal fluid and serum in neurological diseases presents a potential risk for misdiagnosisOskar Stevens-Jones, Clas Malmeström, Clara Constantinescu, et al.
Acta Neurologica Scandinavica|May 17, 2020
Intrathecal immunoreactivity in people with or without previous infectious mononucleosisDaniel Jons, Henrik Zetterberg, Clas Malmeström, et al.
Multiple Sclerosis and Related Disorders|May 13, 2022
Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot studyKalle Johansson, Pontus Wasling, Lenka Novakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 23, 2016
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosisLenka Novakova, Markus Axelsson, Mohsen Khademi, et al.
Journal of Neurochemistry|October 28, 2016
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosisLenka Novakova, Markus Axelsson, Mohsen Khademi, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Chemosphere|August 8, 2024
Sampling of per- and polyfluoroalkyl substances in drainage water from a waste management facilityMio Pettersson, Ingrid Ericson Jogsten, Patrick van Hees, et al.
Frontiers in Neurology|April 3, 2023
The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective surveySofia Sandgren, Lenka Novakova, Markus Axelsson, et al.
Plos One|April 4, 2018
Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkersLenka Novakova, Markus Axelsson, Clas Malmeström, et al.
European Journal of Neurology|April 17, 2026
Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple SclerosisIgal Rosenstein, Markus Axelsson, Magnus Johnsson, et al.
Multiple Sclerosis and Related Disorders|October 11, 2021
Follow-up after infectious mononucleosis in search of serological similarities with presymptomatic multiple sclerosisDaniel Jons, Linn Persson Berg, Peter Sundström, et al.
European Journal of Neurology|June 14, 2023
Presence of neural surface and onconeural autoantibodies in cerebrospinal fluid and serum in neurological diseases presents a potential risk for misdiagnosisOskar Stevens-Jones, Clas Malmeström, Clara Constantinescu, et al.
Acta Neurologica Scandinavica|May 17, 2020
Intrathecal immunoreactivity in people with or without previous infectious mononucleosisDaniel Jons, Henrik Zetterberg, Clas Malmeström, et al.
Multiple Sclerosis and Related Disorders|May 13, 2022
Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot studyKalle Johansson, Pontus Wasling, Lenka Novakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 23, 2016
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosisLenka Novakova, Markus Axelsson, Mohsen Khademi, et al.
Journal of Neurochemistry|October 28, 2016
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosisLenka Novakova, Markus Axelsson, Mohsen Khademi, et al.
Pageof 9